Nothing Special   »   [go: up one dir, main page]

AU2011242402A1 - Method for improving the health of skin - Google Patents

Method for improving the health of skin Download PDF

Info

Publication number
AU2011242402A1
AU2011242402A1 AU2011242402A AU2011242402A AU2011242402A1 AU 2011242402 A1 AU2011242402 A1 AU 2011242402A1 AU 2011242402 A AU2011242402 A AU 2011242402A AU 2011242402 A AU2011242402 A AU 2011242402A AU 2011242402 A1 AU2011242402 A1 AU 2011242402A1
Authority
AU
Australia
Prior art keywords
composition
amount
extract
proanthocyanidin
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011242402A
Inventor
Robert Buist
Ricky Hay
Fiona Keogh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FIT-BIOCEUTICALS Pty Ltd
Original Assignee
Fit Bioceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901649A external-priority patent/AU2010901649A0/en
Application filed by Fit Bioceuticals Ltd filed Critical Fit Bioceuticals Ltd
Priority to AU2011242402A priority Critical patent/AU2011242402A1/en
Publication of AU2011242402A1 publication Critical patent/AU2011242402A1/en
Priority to AU2013100430A priority patent/AU2013100430B4/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/87Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods for improving the health of the skin of a subject by the oral administration of a composition comprising resveratrol, a proanthocyanidin, grape skin extract and vitamin C are described.

Description

WO 2011/130787 PCT/AU2011/000451 1 Method for improving the health of skin Field of the Invention The present invention relates to a method for improving the health of the skin of a subject by 5 administration of an oral composition. Background of the Invention Many people seek to improve the visual appearance of their skin. As a result, a great deal of research has focused on developing products which are capable of improving the characteristics of io skin which are responsible for its appearance, It is believed that skin appearance is influenced to an extent by the health and condition of the lower layers of the dermis and the dermoepidermal junction (DEJ). However, most commercially available skin care products are adapted for topical application, meaning that at best the active ingredients therein penetrate only several layers of skin and are ultimately unable to reach or penetrate the lower layers of the dermis or the DEJ. There is is therefore a need for methods in which the health and condition of the lower layers of the dermis and the DEJ can be optimised so as to improve the visual appearance of the skin. Summary of the Invention In a first aspect, the present invention provides a method for improving the health of the skin of a 20 subject, the method comprising oral administration to the subject of a composition comprising resveratrol, a proanthocyanidin, grape skin extract and vitamin C. The grape skin extract may be obtained from Vitis vinifera. 25 The amount of grape skin extract present in the composition may be between about 10 mg and about 200 mg. In one embodiment the amount of grape skin extract present in the composition is about 30 mg. The amount of resveratrol present in the composition may be between about 25 mg and about 3o 300 mg. In one embodiment the amount of resveratrol present in the composition is about 100 mg. The resveratrol may be present in the composition as an extract. The extract may be obtained from WO 2011/130787 PCT/AU2011/000451 2 Polygonum cuspidatum or Polygonum sachalinense. The amount of the proanthocyanidin present in the composition may be between about 15 mg and about 80 mg. In one embodiment the amount of the proanthocyanidin present in the composition is s about 47.5 mg. The proanthocyanidin may be present in the composition as an extract. The extract may be obtained from grape seed. The grape may be Vitis vinifera. io The amount of vitamin C present in the composition may be between about 25 mg and about 200 mg. In one embodiment the amount of vitamin C present in the composition is about 50 mg. The composition may further comprise quercetin. The amount of quercetin present in the composition may be between about 10 mg and about 100 mg. In one embodiment the amount of 15 quercetin present in the composition is about 40 mg. The compositions may be synergistic. The composition may further comprise one or more pharmaceutically acceptable excipients, 20 diluents or adjuvants. The composition may be in the form of a unit dosage form, for example tablets, capsules or caplets. The method may involve administration of between 1 and 5 dosage forms per day. 25 The composition may be in the form of a food stuff or beverage. In a second aspect, the present invention provides a method for improving the health of the skin of a subject, the method comprising oral administration to the subject of a composition in unit dosage 30 form comprising about 95 mg to about 105 mg resveratrol, about 45 mg to about 50 mg of a proanthocyanidin, about 28 mg to about 32 mg of a grape skin extract, and about 38 mg to about 40 mg of vitamin C to a subject.
WO 2011/130787 PCT/AU2011/000451 3 In one embodiment the composition comprises about 100 mg of resveratrol, about 47.5 mg of a proanthocyanidin, about 30 mg of grape skin extract and about 50 mg of vitamin C. The composition may further comprise about 40 mg quercetin. .5 Definitions Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. 10 In the context of this specification, the terms "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element. is In the context of this specification, the term "proanthocyanidin" refers to flavanol compounds, and in particular oligomers comprising at least one flavanol moiety. Examples of proanthocyanidins include catechins, such as epigallocatechin 3-gallate (EGCG) In the context of this specification, the term "extract" refers to an active preparation derived from 20 one or more plants. In the context of this specification "active" means that the extract is capable of producing a desired therapeutic or cosmetic benefit as disclosed herein. An extract is obtained by a process of "extraction" which will be understood by those skilled in the art as, in general terms, treatment of plant material (for example, fruit, fruit skin, leaves, seed, bark, roots, stems and the like) with a solvent, a liquid, or a supercritical fluid to dissolve the active compound(s) and separate 25 the same from residual unwanted plant material. An extract may be in liquid form (for example as a decoction, solution, infusion or tincture) or solid form (for example as a powder or granules). In the context of this specification, the term "pharmaceutically acceptable" means that 'the compound to which it refers is suitable for use in contact with tissues of the body without undue 30 toxicity, incompatibility, instability, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
WO 2011/130787 PCT/AU2011/000451 4 In the context of this specification, the terms "improve" and "improving" refer to the ability to achieve a measurable benefit in relation to the health of skin (such as the appearance and/or texture of the skin), or otherwise prevent, hinder, retard, or reverse the deterioration in the appearance of the skin in any way whatsoever. Thus the terms "improve", "improving' and the like are to be considered in 5 their broadest context. In the context of this specification, "food", "foods", "beverage" or "beverages" includes but is not limited to health foods, functional foods and foods for specified health use. When such food or beverage of the present invention is used for subjects other than humans, the term can be used to io include a feedstuff. In the context of this specification, the term "about," is understood to refer to a range of numbers that a person of skill in the art would consider equivalent to the recited value in the context of achieving the same function or result. 15 In the context of this specification, the term "subject" includes humans, primates, livestock animals (eg. sheep, pigs, cattle, horses, donkeys), laboratory test animals (eg. mice, rabbits, rats, guinea pigs), companion animals (eg. dogs, cats) and captive wild animals (eg. foxes, kangaroos, deer). Typically, the subject is a human or a laboratory test animal. Even more typically, the subject is a 20 human. Detailed Description of the Invention The present inventors have surprisingly discovered that it is possible to improve the health of the skin of a subject by the oral administration to the subject of a composition comprising resveratrol, a 25 proanthocyanidin, grape skin extract and vitamin C. The compositions of the present invention provide an optimal combination of nutritional ingredients which, when administered orally, nourish the lower layers of the dermis and the DEJ. The compositions of the present invention may improve the health of the skin of a subject by 30 providing cosmetic improvements including: - anti-ageing effects - reduction in wrinkles or visible lines - improved skin texture - protection against oxidative stress WO 2011/130787 PCT/AU2011/000451 5 - promotion of collagen production - skin lightening effects - promotion of skin repair - improvement in collagen cross-linking s - supporting the skin barrier function - increasing skin radiance In accordance with particular embodiments of the invention the amount of resveratrol present in the composition may be between about 25 mg and about 300 mg, or more typically between about io 25 mg and about 200 mg, or between about 50 mg and about 150 mg. Alternatively, the composition may comprise about 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, or 145 mg of resveratrol. 15 The resveratrol may be present in the composition in a highly pure form (for example greater than 98% pure), or alternatively as part of an extract. The extract may be obtained from Polygonum cuspidatum or Polygonum sachalinense, or indeed any other plant or part thereof which contains resveratrol (for example cranberries, blueberries, mulberries, raspberries and certain pine trees). The resveratrol may be present in the composition in the form of a salt or derivative thereof. 20 Suitable derivatives include compounds wherein one or more of the hydroxy groups are derivatised, for example acylated or alkylated. In accordance with particular embodiments of the invention the amount of proanthocyanidin present in the composition may be between about 15 mg and about 80 mg, or between about 25 mg and 25 about 60 mg, or between about 35 mg and about 55 mg. Alternatively, the composition may comprise about 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, or 54 mg of a proanthocyanidin. 30 The proanthocyanidin may be present in the composition in a highly pure form (for example greater than 98% pure), or alternatively as part of an extract. The proanthocyanidin may be obtained from grape seed, for example grape seed of Vitis vinifera. Those skilled in the art will appreciate that the proanthocyanidin may also be extracted from many other plants or parts thereof, for example, apples, pine bark, cinnamon, cocoa, grape skin, bilberries, cranberries, chokeberries, WO 2011/130787 PCT/AU2011/000451 6 blackcurrants, green tea, black tea, Quercus petraea and Quercus robur heartwood. The proanthocyanidin may be present in the composition in the form of a salt or derivative thereof. Suitable derivatives include compounds wherein one or more of the hydroxy groups are derivatised, for example acylated or alkylated. 5 In accordance with particular embodiments of the invention the amount of grape skin extract present in the composition may be between about 10 mg and about 200 mg, or between about 10 mg and about 100 mg, or between about 20 mg and about 50 mg. Alternatively, the composition may comprise about 25 mg, 30 mg, 35 mg, 40 mg, or 45 mg of grape skin extract. 10 The grape skin extract may be obtained from any species of the Vitis genus. The species may be Vitis vinifera. Those skilled in the art will appreciate that the grape skin extract may also be obtained from other species of the Vitis genus, including but not limited to Vitis mustangensis, Vitis aestivalis, Vitis riparia, Vitis rotundifolia, and Vitis labrusca. 15 In accordance with particular embodiments of the invention the amount of vitamin C present in the composition may be between about 25 mg and about 200 mg, or between about 25 mg and about 100 mg, or between about 35 mg and about 65 mg. Alternatively, the composition may comprise about 40 mg, 45 mg, 50 mg, 55 mg, or 60 mg vitamin C. 20 The compositions of the invention are administered orally and may be conveniently presented in 'unit dosage form and prepared by any of the methods well known in the art of pharmacy. The method may include the step of bringing the components of the composition into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are 25 prepared by uniformly and intimately bringing into association the components of the composition with a liquid carrier or finely divided solid carrier, or both and then, if necessary, shaping the product into the desired composition. Compositions suitable for oral administration May be presented as discrete units (i.e. dosage 30 forms) such as gelatine or HPMC capsules, cachets or tablets, each containing a predetermined amount of each component of the composition as a powder, granules, as a solution or a suspension in an aqueous liquid or a non-aqueous liquid, or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
WO 2011/130787 PCT/AU2011/000451 7 When the composition is formulated as capsules, the components of the composition may be formulated with one or more pharmaceutically acceptable carriers such as starch, lactose, microcrystalline cellulose and/or silicon dioxide. Additional ingredients may include lubricants such as magnesium stearate and/or calcium stearate. Tablets may be prepared by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the components of the composition in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant (for example magnesium stearate or calcium stearate), inert diluent io or a surface active/dispersing agent. Moulded tablets may be made by moulding a mixture of the powdered composition moistened with an inert liquid diluent, in a suitable machine. The tablets may optionally be. coated, for example, with an enteric coating and may be formulated so as to provide slow or controlled release of the composition therein. 15 Between 1 and 5 unit dosage forms may be administered per day. However, the skilled addressee will also appreciate that the specific dosing regimen (with respect for example to frequency and duration of administration) to be employed in accordance with embodiments of the invention may be determined on a case-by-case basis. Such determinations are well within the capabilities of those skilled in the art without undue burden or experimentation. 20 Further, it will be understood that the specific dose level of a composition of the invention for any particular individual will depend upon a variety of factors including, for example, the activity of the resveratrol, proanthocyanidin, grape skin and vitamin C employed, the age, body weight, general health and diet of the individual to be treated, the time of administration, rate of excretion, and 25 combination with any other treatment or therapy. Single or multiple daily administrations can be carried out with dose levels. A broad range of doses may be applicable. The present invention contemplates combination therapies, wherein compositions as disclosed herein are coadministered with other suitable treatments which may facilitate the desired cosmetic 30 effect. For example, one may seek to aid the improvement of the appearance of the skin using additional selected oral supplements or selected topical compositions in combination by coadministration or sequential administration with the compositions disclosed herein. By "coadministered" is meant simultaneous administration in the same formulation or in two different formulations via the same or different routes or sequential administration by the same or different WO 2011/130787 PCT/AU2011/000451 8 routes. By "sequential" administration is meant a time difference of from seconds, minutes, hours or days between the administration of the two types of composition. The compositions may be administered in any order. s The present invention contemplates the administration of the composition in a food or beverage. The food may be a solid form or a liquid form. Specific examples of the types of foods or beverages include, but are not limited to soft drinks, carbonated drinks, nutritional beverages, fruit beverages, and milk beverages (including a concentrated stock solution of such a beverage and a dry powder for preparation of such a beverage); confectionery such as chewing gum and chocolate; 1o dairy products such as milk, yogurt, butter, and cheese. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms 1s part of the common general knowledge in the field of endeavour to which this specification relates. The present invention will now be described with reference to the following specific examples, which should not be construed as in any way limiting the scope of the invention. 20 Examples Example I -Oral composition By way of example only a suitable oral composition for use in accordance with the invention is outlined below. The following is to be construed as merely an illustrative example of a composition 25 and not as a limitation of the scope of the present invention in any way. A typical composition for oral administration is outlined below: Each capsule or tablet comprises: Herbal extracts equiv. to dry: 30 Polygonum cuspidatum (giant knotweed) root 20-g equiv. resveratrol 100 mg Vitis vinifera (grape) seed 6 g equiv. proanthocyanidins 47.5 mg Vitis vinifera (grape) skin 30 mg WO 2011/130787 PCT/AU2011/000451 9 Nutrients: Ascorbic acid (vitamin C) 50 mg Quercetin 40 mg Dosage: 1 capsule or tablet once to three times daily.

Claims (26)

1. A method for improving the health of the skin of a subject, the method comprising oral administration to the subject of a composition comprising resveratrol, a proanthocyanidin, s grape skin extract and vitaminC.
2. A method according to claim 1, wherein the grape skin extract is obtained from Vitis vinifera. 10
3. A method according to claim 1 or claim 2, wherein the amount of the grape skin extract in the composition is from about 10 mg to about 200 mg.
4. A method according to any one of claims 1 to 3, wherein the amount of the grape skin extract in the composition is about 30 mg. 15
5. A method according to any one of claims 1 to 4, wherein the amount of resveratrol in the composition is from about 25 mg to about 300 mg.
6. A method according to any one of claims 1 to 5, wherein the amount of resveratrol in the 20 composition is about 100 mg.
7. A method according to any one of claims 1 to 6, wherein the resveratrol is present in the composition as an extract. 25
8. A method according to claim 7, wherein the extract is obtained from Polygonum cuspidatum or Polygonum sachalinense.
9. A method according to any one of claims 1 to 8, wherein the amount of the proanthocyanidin in the composition is from about 15 mg to about 80 mg. 30
10. A method according to any one of claims 1 to 9, wherein the amount of the proanthocyanidin in the composition is about 47.5 mg. WO 2011/130787 PCT/AU2011/000451 11
11. A method according to any one of claims 1 to 10, wherein the proanthocyanidin is present in the composition as an extract.
12. A method according to claim 11, wherein the extract is obtained from grape seed. 5
13. A method according to claim 12, wherein the grape is Vitis vinifera.
14. A method according to any one of claims 1 to 13, wherein the amount of the vitamin C in the composition is from about 25 mg to about 200 mg. 10
15. A method according to any one of claims 1 to 14, wherein the amount of the vitamin C in the composition is about 50 mg.
16. A method according to any one of claims 1 to 15, wherein the composition further 15 comprises quercetin.
17. A method according to claim 16, wherein the amount of quercetin in the composition is from about 10 mg to about 100 mg. 20
18. A method according to claim 16 or claim 17, wherein the amount of quercetin in the composition is about 40 mg.
19. A method according to any one of claims 1 to 18, wherein the composition further comprises one or more pharmaceutically acceptable excipient, diluent or adjuvant. 25
20. A method according to any one of claims 1 to 19, wherein the composition is in the form of a unit dosage form.
21. A method according to any one of claim 20, wherein the unit dosage form is a tablet, a 30 capsules or a caplet.
22. A method according to any one of claim 20 or claim 21, wherein between 1 and 5 unit dosage forms are administered per day. WO 2011/130787 PCT/AU2011/000451 12
23. A method according to any one of claims 1 to 18, wherein the composition is in the form of a food stuff or beverage. s
24. A method for' improving the health of the skin of a subject, the method comprising oral administration to the subject of a composition in unit dosage form comprising about 95 mg to about 105 mg resveratrol, about 45 mg to about 50 mg of a proanthocyanidin, about 28 mg to about 32 mg of a grape skin extract, and about 38 mg to about 40 mg of vitamin C to a subject. 10
25. A method according to claim 24, wherein the composition comprises about 100 mg resveratrol, about 47.5 mg of a proanthocyanidin, about 30 mg of a grape skin extract, and about 40 mg of vitamin C. 15
26. A method according to claim 24 or claim 25, wherein the composition further comprises about 40 mg quercetin.
AU2011242402A 2010-04-20 2011-04-20 Method for improving the health of skin Abandoned AU2011242402A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2011242402A AU2011242402A1 (en) 2010-04-20 2011-04-20 Method for improving the health of skin
AU2013100430A AU2013100430B4 (en) 2010-04-20 2013-04-08 Method for improving the health of skin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2010901649 2010-04-20
AU2010901649A AU2010901649A0 (en) 2010-04-20 Method for improving the health of skin
PCT/AU2011/000451 WO2011130787A1 (en) 2010-04-20 2011-04-20 Method for improving the health of skin
AU2011242402A AU2011242402A1 (en) 2010-04-20 2011-04-20 Method for improving the health of skin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013100430A Division AU2013100430B4 (en) 2010-04-20 2013-04-08 Method for improving the health of skin

Publications (1)

Publication Number Publication Date
AU2011242402A1 true AU2011242402A1 (en) 2012-12-06

Family

ID=44833553

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011242402A Abandoned AU2011242402A1 (en) 2010-04-20 2011-04-20 Method for improving the health of skin

Country Status (2)

Country Link
AU (1) AU2011242402A1 (en)
WO (1) WO2011130787A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3017289B1 (en) * 2014-02-07 2017-05-05 Caudalie HIGH-STRENGTH ANTIOXIDANT POWDER COMPOSITION BASED ON POLYOHENOL DERIVATIVES AND COSMETIC APPLICATION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202258D0 (en) * 2002-01-31 2002-03-20 Dodson & Horrell Ltd Annimal feed supplement
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
CA2546464A1 (en) * 2005-05-04 2006-11-04 Richard Wachsberg Sequential application of oral and topical formulations for treating wrinkles and other damage to skin

Also Published As

Publication number Publication date
WO2011130787A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
Gazzani et al. Food components with anticaries activity
KR101733261B1 (en) Composition for promoting lipolysis
KR101498780B1 (en) Composition for preventing or treating hangover
US11357250B2 (en) Treatment and prevention of diabetes and obesity
AU2011242403A1 (en) Combined method for improving the health of skin
JP6434267B2 (en) Capsule
JP2004159563A (en) Propolis composition
Dutta et al. Nutraceuticals from major fruit crops
AU2013100430A4 (en) Method for improving the health of skin
AU2011242402A1 (en) Method for improving the health of skin
JP6757995B2 (en) Oral composition
KR101610894B1 (en) Taste-masked granules containing vitamin C
KR20180107785A (en) Antimicrobial composition comprising organic solvent fractions of arctium lappa root extracts as an effective component
KR20210044762A (en) Anti-microbial composition comprising pinus koraiensis sieb extract
JP2021176837A (en) Composition for preventing, improving and treating periodontitis
KR20180102658A (en) Detoxifying compositions for oral administration and methods for preparing the same
JP2015096498A (en) Ages decomposer
JP7016510B2 (en) Blood cholesterol elevation inhibitory composition
Galante et al. Insights into yerba mate components: Chemistry and food applications
AU2013100431B4 (en) Combined method for improving the health of skin
JP7527032B2 (en) Oral Compositions
JP7562169B2 (en) Composition for suppressing elevation of blood cholesterol
KR102395338B1 (en) Oral composition for improving systemic symptoms including sensitivity to cold
JP7452856B2 (en) Oral composition
JP2019176828A (en) Oral composition

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period